Status of B-Vitamins and Homocysteine in Diabetic Retinopathy: Association with Vitamin-B12 Deficiency and Hyperhomocysteinemia by Satyanarayana, Alleboena et al.
Status of B-Vitamins and Homocysteine in Diabetic
Retinopathy: Association with Vitamin-B12 Deficiency
and Hyperhomocysteinemia
Alleboena Satyanarayana
1, Nagalla Balakrishna
1, Sujatha Pitla
1, Paduru Yadagiri Reddy
1, Sivaprasad
Mudili
1, Pratti Lopamudra
1, Palla Suryanarayana
1, Kalluru Viswanath
2, Radha Ayyagari
3, Geereddy
Bhanuprakash Reddy
1*
1Biochemistry, National Institute of Nutrition, Hyderabad, India, 2Pushpagiri Vitreo Retina Institute, Hyderabad, India, 3Ophthalmology, University of California, San
Diego, San Diego, California, United States of America
Abstract
Diabetic retinopathy (DR) is a common cause of blindness. Although many studies have indicated an association between
homocysteine and DR, the results so far have been equivocal. Amongst the many determinants of homocysteine, B-vitamin
status was shown to be a major confounding factor, yet very little is known about its relationship to DR. In the present
study, we, therefore, investigated the status of B-vitamins and homocysteine in DR. A cross-sectional case–control study was
conducted with 100 normal control (CN) subjects and 300 subjects with type-2 diabetes (T2D). Of the 300 subjects with T2D,
200 had retinopathy (DR) and 100 did not (DNR). After a complete ophthalmic examination including fundus fluorescein
angiography, the clinical profile and the blood levels of all B-vitamins and homocysteine were analyzed. While mean plasma
homocysteine levels were found to be higher in T2D patients compared with CN subjects, homocysteine levels were
particularly high in the DR group. There were no group differences in the blood levels of vitamins B1 and B2. Although the
plasma vitamin-B6 and folic acid levels were significantly lower in the DNR and DR groups compared with the CN group,
there were no significant differences between the diabetes groups. Interestingly, plasma vitamin-B12 levels were found to
be significantly lower in the diabetes groups compared with the CN group; further, the levels were significantly lower in the
DR group compared with the DNR group. Higher homocysteine levels were significantly associated with lower vitamin-B12
and folic acid but not with other B-vitamins. Additionally, hyperhomocysteinemia and vitamin-B12 deficiency did not seem
to be related to subjects’ age, body mass index, or duration of diabetes. These results thus suggest a possible association
between vitamin-B12 deficiency and hyperhomocysteinemia in DR. Further, the data indicate that vitamin-B12 deficiency
could be an independent risk factor for DR.
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Introduction
Diabetic retinopathy (DR) is one of the most common
microvascular complications of diabetes and ranks as a common
cause of blindness worldwide [1,2]. Diabetic retinopathy could
become a major threat to public health in the future due to the
global prevalence of diabetes, which is projected to affect 438
million people by 2030 [3]. Both the duration of diabetes and its
metabolic control have been identified as the risk factors most
strongly associated with the development of DR [4,5]. Diabetic
retinopathy occurs in 70% of all persons having diabetes for more
than 15 years. While the prevalence of DR has varied (20%–60%)
in different studies, a recent study indicated that the estimated
prevalence was 28.5% among US adults [6]. The prevalence of
DR among urban subjects with diabetes in India was reported to
be about 17% [7], whereas in a clinical study it was found to be
34% among patients with type 2 diabetes (T2D) [8]. The
prevalence of DR in South India was reported to be 22.4% based
on the Andhra Pradesh Eye Disease Study (APEDS) of self-
reported diabetes [9]. The prevalence of DR was 0.5% in the
general rural populations of South India and 10.5% among
patients with diabetes [10].
Diabetic retinopathy is characterized by the appearance of
vascular lesions of increasing severity, culminating in the growth of
new vessels. Early or nonproliferative DR (NPDR) is marked by
retinal vascular microaneurysms, blot hemorrhages, cotton-wool
spots, loss of retinal pericytes, increased vascular retinal perme-
ability, alterations in regional blood flow, and abnormal retinal
microvasculature, all of which lead to retinal ischemia. Prolifer-
ative DR (PDR), the more severe state, is marked by the formation
of abnormal, fragile new blood vessels that are prone to
hemorrhage [11,12].
Although the prevalence of DR increases with the duration of
diabetes, studies have shown that intensive glycemic control can
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26747delay its development [4,5]. In principle, all patients with diabetes
might be expected to develop diabetic microvascular complica-
tions if hyperglycemia alone were the triggering factor for diabetic
complications. It is, however, noteworthy that some patients may
still develop DR even with good glycemic control. Conversely,
some patients with poor glycemic control avoid this complication,
notably long-surviving patients with type-1 diabetes (T1D).
Therefore, the impact of strict glycemic control on prevention of
diabetic complications is not that scrupulous [4,5,13]. Multiple
factors are likely to be involved in predisposing diabetes subjects to
complications, as evidenced by many but not all patients with
diabetes developing one or more microvascular complications. If
the predisposing factors are known, it may be possible to delay the
onset and progression of these complications. Hence, there is an
obvious need to understand the risk factors that are associated with
diabetic complications.
Although genetic susceptibility appears to be the primary
predisposing factor for DR (reviewed by Ng, 2010 [14] and Fu et
al, 2010 [15]; [16]), the role of environmental factors like
nutritional and dietary factors are not to be discounted. Vitamins
and mineral supplementation for the management of T2D has
been reported [17], but its role in the prevention and development
of T2D in general and diabetic complications in particular has not
been established clearly. Further, diabetes itself can alter the
nutritional status [18,19], and experiments suggest that patients
with diabetes are prone to deficiency of micronutrients such as
magnesium, zinc, copper, manganese, and chromium. It was
observed that serum ascorbic acid, B-vitamins, and possibly 1,25-
dihydroxycholcalciferol concentrations are low in diabetic pa-
tients. Studies indicate low plasma thiamine (vitamin B1) in both
T1D and T2D patients [20], and high-dose thiamine and its
derivatives such as benfotiamine can prevent the development of
microvascular complications [21]. However, the levels of vitamin
B1 in DR have not been investigated so far.
Low concentrations of folic acid and other B vitamins are
associated with increased risk of vascular damage through
homocysteine. Homocysteine has been extensively studied in
recent years as a biomarker as well as a risk factor for vascular
diseases, including vaso-occlusive diseases of the eye [22–26].
Homocysteine is a by-product of transmethylation reactions and
detoxified by methionine synthetase, which is dependent on
vitamin B12 and folate as coenzymes for its proper function
[27,28]. Determinants of hyperhomocysteinemia such as low
concentrations of folate and B-vitamin coenzymes and altered
activities of enzymes involved in the breakdown of homocysteine
are also associated with increased risk of cardiovascular compli-
cations [26]. Nevertheless, B-vitamin status and its contribution to
hyperhomocysteinemia in DR have not been examined. There-
fore, we investigated the status of B-vitamins (B1, B2, B6, B12,
folic acid) and homocysteine in DR.
Results
This is a hospital-based case-control study consisting of T2D
subjects with (DR) and without retinopathy (DNR) along with
normal control (CN) subjects. The characteristics of the CN,
DNR, and DR groups are shown in Table 1. The sex distribution
was approximately the same in all the groups (male and female
were, respectively, 58% and 42% in CN, 56% and 44% in DNR,
and 55% and 45% in DR). Further, there was no significant
difference between male and female subjects in all three groups
with respect to demographics and measured parameters. There-
fore, the data for both men and women were pooled as a whole in
the respective groups. Mean age, body mass index (BMI), and
hemoglobin levels were comparable between the groups. The
duration of diabetes was matched for DNR and DR (p.0.05).
Amongst diabetes groups, glycosylated hemoglobin (HbA1c) levels
were higher in DR compared to DNR (p,0.05). While plasma
total cholesterol and low-density lipoprotein (LDL) were compa-
rable between the groups, triglyceride levels were higher and high-
density lipoprotein (HDL) was lower in the diabetes groups
compared with the CN group (Table 1). Nevertheless, the levels of
triglycerides and HDL were comparable between the DNR and
DR groups.
The mean plasma homocysteine levels were significantly higher
in the DNR group compared with the CN group, and a further
increase (p,0.05) was found in the DR group compared with the
DNR group (Figure 1). However, there was a considerable overlap
of hyperhomocysteinemia between the DNR and DR groups.
Hence, we determined the prevalence of hyperhomocysteinemia
Table 1. Clinical and demographic profile of control (CN) and diabetes patients without (DNR) and with retinopathy (DR).
Parameter
Normal
(n=100)
DNR
(n=100)
DR
(n=194) F –Value P –Value
Age (years) 53.9969.22
a 54.7669.29
a 55.7568.24
a 2.1 0.128
BMI 23.6363.04
a 25.2164.19
a 24.3264.45
a 1.6 0.212
Hb (g/dL) 14.8961.73
a 14.3162.16
a 14.1162.32
a 1.4 0.255
Duration (years) - 10.1666.92
a 11.0366.92
a 2.2 0.098
Glucose (mg/dL) 99.16618.86
a 209.97685.10
b 221.28691.36
b 146.8 0.000
HbA1c (%) 5.6461.14
a 8.9462.49
b 10.3362.94
c 86.0 0.000
Insulin (mU/mL) 29.1469.94
a 38.05622.71
a 34.75619.58
a 1.4 0.255
Total Cholesterol (mg/dL) 169.39639.65
a 167.03653.56
a 178.01658.47
a 0.6 0.552
Triglycerides (mg/dL) 129.78663.57
a 151.99665.43
b 163.00677.90
b 4.3 0.015
HDL (mg/dL) 35.0268.81
a 30.0969.21
b 28.7067.41
b 8.8 0.000
LDL (mg/dL) 112.69630.13
a 110.66629.01
a 117.11634.05
a 0.6 0.570
Note: 1. Values are Mean 6 SD.
2. Variables of glucose, HbA1c and TC were transformed into logarithmic values due to heterogeneity of variances across groups and mean values across groups were
compared by oneway ANOVA ‘F’ test with post hoc test of Tukey’s multiple comparisons.
3. Significant differences (p,0.05) of mean values between the groups are indicated by different superscript letters.
doi:10.1371/journal.pone.0026747.t001
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the groups: 65% in DR, 46% in DNR, and 11% in CN (Figure 2).
Further, we also compared the homocysteine levels in DR patients
with a shorter duration of diabetes (,5 years) with those of DNR
patients with a long duration of diabetes (.5 years). The mean
value of homocysteinemia in DNR of .5 years duration was
12.4 mmol/L, while it was 14.2 mmol/L in DR of ,5 years
duration. In addition, when duration was controlled for in both
DNR and DR groups, DR patients had significantly higher levels
of homocysteine than DNR patients. Together, these results
suggest an association between hyperhomocysteinemia and DR.
Since B-vitamins are linked to homocysteine metabolism and
homeostasis, we then determined the B-vitamin levels. The
vitamin B1 levels were marginally (but statistically significantly)
higher in DNR compared with the CN group, but there was no
significant difference between the DNR and DR groups.
Furthermore, vitamin B1 levels were comparable between the
DR and CN groups. While the blood levels of vitamin B2 were
comparable between the groups, plasma vitamin B6 levels were
significantly lower (p,0.05) in the diabetes groups (DNR and DR)
compared with the CN group (Table 2). In spite of the deficiency
of vitamin B6 in the diabetes groups, there was no significant
difference in the mean levels of vitamin B6 between the DNR and
DR groups (Table 2). Similarly, plasma folic acid levels were lower
but not deficient in the diabetes groups (DNR and DR) compared
with the CN group; however, the levels were comparable between
the DNR and DR groups (Table 2). Plasma vitamin B12 levels
were significantly lower (p,0.01) in diabetes patients (DNR and
DR) compared with the CN subjects (Figure 3). Interestingly, in
this study significantly lower (p,0.05) plasma vitamin B12 levels
were observed in DR patients compared with DNR patients
(Figure 3). The mean vitamin B12 levels in the DR group were
below the normal range (200–1000 pg/mL). However, the vitamin
B12 levels ranged from 20 to 1500 pg/mL with considerable
overlap between the groups. Therefore, we examined the data for
prevalence of vitamin B12 deficiency in the three groups. With
200 pg/mL as the cut-off level for deficiency [29–31], the
prevalence of vitamin B12 deficiency was significantly different
(p,0.001) between the groups; 67% in DR, 54% in DNR, and
41% in CN (Figure 4). The ratio of vitamin B12 to folic acid was
also significantly different (p,0.05) between CN and DR groups,
but not between the DNR and DR groups (data not shown).
However, there was no significant difference in homocysteine and
vitamin B12 levels between NPDR and PDR patients (14.72 vs.
14.11 mmol/L and 182 vs. 177 pg/mL, respectively). These results
suggest that DR is associated with a higher prevalence of vitamin
B12 deficiency.
Homocysteine levels were inversely related (p,0.05) to vitamin
B12 and folic acid but not to vitamins B1, B2, and B6, when data
of all the groups were considered (Table 3). Interestingly,
irrespective of groups, homocysteine levels were significantly
(p,0.05) associated with glucose and HbA1c levels but not
related to subjects’ age, BMI, or duration of diabetes (Table 3).
Likewise, vitamin B12 levels were significantly (p,0.05) but
inversely associated with glucose, HbA1c, and homocysteine and
positively related with folic acid but not with age, BMI, or duration
(Table 3). Considering that plasma folic acid levels were low but
Figure 1. Plasma homocysteine levels. Data represent mean 6 SE
in control (CN; n=75) and diabetes patients without (DNR; n=75) and
with retinopathy (DR; n=150). Data were transformed into log values
and compared mean values across groups by oneway ANOVA ‘F’ test
with post hoc test of Tukey’s multiple comparisons. Significant
differences (p,0.05) of mean values between the groups are indicated
by different letters on the bars after adjusting the duration of diabetes
between DNR and DR.
doi:10.1371/journal.pone.0026747.g001
Figure 2. Prevalence (%) of hyperhomocysteinemia (.12 mmol/
L) in control (CN) and diabetes patients without (DNR) and with
retinopathy (DR). Data indicate percent of subjects above 12 mmol/L
of the respective group. Significant differences (p,0.05) of mean values
between the groups are indicated by different letters on the bars after
adjusting the duration of diabetes between DNR and DR.
doi:10.1371/journal.pone.0026747.g002
Table 2. Blood and plasma levels of vitamins B1, B2, B6 and
folic acid of control (CN) and diabetes patients without (DNR)
and with retinopathy (DR).
Vitamin CN DNR DR F Value P-values
B1
(ng/mL)
67.663.1
a
n=45
70.163.8
b
n=45
67.263.0
ab
n=45
3.9 0.024
B2
(ng/mL)
23169.3
a
n=45
24868.2
a
n=45
23867.0
a
n=45
1.99 0.143
B6
(ng/mL)
20.661.3
a
n=45
13.061.1
b
n=45
14.661.0
b
n=60
10.1 0.000
Folic acid
(ng/mL)
10.060.9
a
n=75
7.860.6
ab
n=75
7.260.4
b
n=150
4.7 0.009
Note: 1. Values are Mean 6 SD.
2. Mean values across groups were compared by oneway ANOVA ‘F’ test with
post hoc test of Tukey’s multiple comparisons.
3. Significant differences (p,0.05) of mean values between the groups are
indicated by different superscript letters.
doi:10.1371/journal.pone.0026747.t002
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comparable irrespective of the presence of DR, the odds ratio
for vitamin B12 is twice (95% CI, 1.1–3.7) in the DR group
compared with the DNR group after adjusting for age and
duration of diabetes.
Discussion
Approximately 5% of the global prevalence of blindness is
considered to be due to DR, with estimates of 15%–17% in
developed countries [1]. Nutritional status, particularly micronu-
trients, may affect the risk of DR by influencing the biochemical
mechanisms underlying DR. A biochemical indicator that has
generated considerable interest as a risk factor for many vascular
diseases, including DR, is homocysteine. Although many studies
have evaluated the association between homocysteine and DR,
the results are varied and inconsistent [22,25,32–34]. Amongst
the many determinants of homocysteine, B-vitamin status is a
major confounding factor [23,28,35,36]. However, very little is
known about the extent to which B-vitamin status is associated
with DR vis-a `-vis homocysteine. Considering the general
prevalence of micronutrient deficiency and its contribution to
many metabolic disorders, such as intrauterine growth retarda-
tion, diabetes, and cardiovascular diseases in India [29–31],
determining the status of micronutrients with regard to the
prevalence and pathogenesis of DR is critical. Therefore, we
evaluated the association of B-vitamin status and homocysteine
with DR in a systematic way. To the best of our knowledge, a
relationship between B-vitamin status, homocysteine, and DR has
so far not been reported.
The results of the present study show that while lower levels of
folic acid and vitamins B6 and B12 were observed in patients with
diabetes irrespective of the presence of retinopathy, only vitamin
B12 deficiency was associated with DR. Interestingly, a significant
association was revealed between DR and hyperhomocysteinemia
based on plasma homocysteine levels. Hyperhomocysteinemia has
several causes, including dietary deficiencies of folic acid and
vitamins B6 and B12. Furthermore, supplementation of folic acid
and vitamin B12 is known to reduce homocysteine levels [23,26].
Lack of vitamin B12 is thought to be a more important
determinant for increased homocysteine, particularly in older
people, and it becomes the limiting nutrient for maintaining
normal plasma concentrations once folate levels are optimized. It
should be noted in the present study that the mean age of the
subjects was 55 years and the folate levels were still in the normal
range, although lower mean levels were found in patients with
diabetes. In addition, plasma homocysteine in diabetes varies
depending on the presence or absence of nephropathy. However,
in this study the increased levels of homocysteine were
independent of renal failure because we excluded DNR and DR
patients with renal complications. Therefore, lower vitamin B12
status appears to be a determining factor for increased
homocysteine in DR patients in this population. Further, vitamin
B12 levels did not seem to be influenced by patients’ age, BMI, or
Table 3. Correlations of vitamin-B12 and homocysteine with
demographic and other biochemical parameters.
Parameter Vitamin-B12 Homocysteine
r-value p-value r-value p-value
Age 0.111 0.055 0.088 0.328
Duration 0.074 0.263 0.162 0.113
BMI 0.082 0.292 0.083 0.493
Glucose 20.177 0.016 0.444 0.000
HbA1c 20.192 0.034 0.247 0.047
Vitamin -B1 20.064 0.571 0.294 0.066
Vitamin -B2 20.062 0.577 0.284 0.056
Vitamin -B6 0.047 0.614 20.137 0.383
Folic acid 0.473 0.000 20.323 0.002
Vitamin -B12 --20.485 0.000
Homocysteine 20.485 0.000 - -
Correlations (r-value) were assessed by Spearman rank correlation. While
positive r-value indicates direct correlation, negative r-value indicates inverse
relationship between the variables.
doi:10.1371/journal.pone.0026747.t003
Figure 3. Plasma vitamin-B12 levels. Data represent mean 6 SE in
control (CN; n=75) and diabetes patients without (DNR; n=75) and
with retinopathy (DR; n=150). Data were transformed into log values
and compared the mean values across groups by oneway ANOVA ‘F’
test with post hoc test of Tukey’s multiple comparisons. Significant
differences (p,0.05) of mean values between the groups are indicated
by different letters on the bars.
doi:10.1371/journal.pone.0026747.g003
Figure 4. Prevalence (%) of vitamin-B12 deficiency in control
(CN) and diabetes patients without (DNR) and with retinopathy
(DR). Data indicate percent of subjects below 200 pg/mL of the
respective group. Proportion Z test was done to compare prevalence
between groups. Significant differences (p,0.001) of mean values
between the groups are indicated by different letters on the bars.
doi:10.1371/journal.pone.0026747.g004
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and these variables were not statistically significant. Moreover,
vitamin B12 deficiency is two times as likely in the DR group
compared with the DNR group after adjusting for age and
duration of diabetes. Together, these results also suggest that
vitamin B12 deficiency could be an independent risk factor for
DR.
The Age-Related Eye Disease Study (AREDS) has shown that
antioxidant and trace element micronutrients can reduce the risk
of developing age-related macular degeneration [37–39]. Supple-
mentation with some antioxidants and micronutrients, including
vitamin B1 (benfotiamine), has shown encouraging results in
experimental models of DR and human studies, though the
findings of clinical trials with these antioxidant micronutrients
have been less conclusive [40–42]. Interestingly, a study showed
that AREDS-based micronutrients proven to be beneficial in
ameliorating the lesions associated with DR in experimental rats
[43]. Although we have yet to analyze the association of
micronutrients other than B-vitamins with DR, the results
reported here imply that a deficiency or inadequacy of vitamin
B12 may predispose diabetes patients to DR. Lowered levels of
cobalt, an integral component of vitamin B12 (cyanocobalamine),
paired with decreased dietary intake of vitamin B12 in the DR
group compared with the DNR group further supports the above
implication (GBR unpublished data). It should be noted that low
levels of vitamin B12 have been recognized in Indians for a long
time and recent studies confirm low concentrations of vitamin B12
and the implications for diabetes and cardiovascular diseases in
India [29,30,44]. Our study also further substantiates the general
prevalence of vitamin B12 deficiency in India; about 40% adults
above 50 years are deficient and the prevalence is much higher in
patients with diabetes. This is the first study to show an association
of B-vitamins with DR, and more controlled prospective studies
are warranted to confirm the role of vitamin B12 deficiency in the
development of DR.
Methods
Study design, subjects, and sample collection
This is a hospital-based case–control study conducted during
April 2008 to March 2010 consisting of 300 T2D patients either
with or without retinopathy (DR, n=200 and DNR, n=100,
respectively). In addition, we recruited 100 control (CN) subjects
consisting of partners, relatives, and friends of patients and
employees of the National Institute of Nutrition matched for
similar socioeconomic status of the T2D patients. The CN group
consisted of asymptomatic subjects of age 50 years and above
without any history of cardiovascular and renal complications.
Subjects with T2D with and without retinopathy were recruited
from patients attending the Pushpagiri Vitreo Retina Institute
and were matched for duration of diabetes. Control and diabetes
subjects on nutritional supplements for the last 6 months and
those with a history of nephropathy (based standard renal
function tests) and complications other than DR were excluded.
However, many subjects with diabetes (DR and DNR) used
antidiabetic medication per their physician’s advice. History or
presence of diabetic complications other than DR was assessed by
clinical as well as biochemical methods. All patients with diabetes
underwent a complete ophthalmic examination consisting of best
corrected visual acuity, slit-lamp biomicroscopy, indirect oph-
thalmoscopy, and fundus fluorescein angiography. Diabetic
retinopathy grading was done using the Early Treatment
Diabetic Retinopathy Study adaptation of the modified Airlie
House classification system, and DR was further categorized as
NPDR and PDR [11,45,46]. The study was carried out in
accordance with the guidelines of the Helsinki Declaration of
1975 and approved by the Institutional Ethics Committees of
Pushpagiri Vitreo Retina Institute and National Institute of
Nutrition. After obtaining written informed consent from all
participants, venous blood samples were collected in EDTA tubes
in the morning following an overnight fast. An aliquot of each
whole blood sample was kept, while the remainder was separated
into plasma and red blood cells [46].
Biochemical estimations
Fasting blood glucose was estimated in plasma by the glucose
oxidase–peroxidase method using a kit (BioSystems, Barcelona,
Spain). Glycosylated hemoglobin (HbA1c) was estimated in whole
blood by ion-exchange chromatography using a kit (BioSystems).
While plasma insulin was estimated by a radioimmunoassay kit
(Board of Radiation and Isotope Technology-Department of
Atomic Energy, Mumbai, India), the lipid profile (total cholesterol,
triglycerides, HDL) was analyzed using commercially available kits
(BioSystems).
Estimation of homocysteine and B-vitamins
We employed HPLC to estimate vitamins B1, B2, and B6. The
levels of vitamin B1 and B2 in whole blood and B6 in plasma were
measured as total thiamine pyrophosphate, flavin adenine
dinucleotide, and pyridoxal-59-phosphate, respectively, based on
previously reported methods [47] using commercially available
HPLC kits (Recipe Chemicals and Instruments GmbH, Ger-
many). Plasma levels of vitamin B12 and folic acid were measured
by a solid phase radioimmunoassay method using a commercially
available kit designed for simultaneous measurement of these
vitamins (Siemens Medical Solutions Diagnostics, Los Angeles,
CA, USA). Radioactivity was measured by a gamma counter with
a dual channel for determining
57Co and
125I simultaneously
(Perkin Elmer, 3 wizard 1480, USA). Plasma total homocysteine
levels were measured by HPLC using a Supelcosil
TM LC-18-DB
(150 mm by 4.6 mm) column according to methods reported
previously [48,49].
Statistical analysis
Statistical analysis was performed using SPSS for Windows
version 15.0. Mean and SD or SE values of vitamins and
homocysteine, BMI, age, and duration of disease were calculated.
No outliers were found in the data based on Grubb test.
Comparison of mean values of these variables across groups was
done by one-way ANOVA F test with post hoc Tukey test. Log
transformations were also performed to stabilize the normality of
the skewed variables for glucose, HbA1c, HDL, homocysteine,
and vitamin B12. Proportion Z test was used for comparison of
prevalence of vitamin B12 deficiency. The relationship between
homocysteine and vitamin B12 with age, duration of disease, BMI,
glucose, and vitamins B1, B2, B6, and folic acid was calculated by
Spearman rank correlation coefficients, and risk was estimated by
odds ratio with logistic regression model. Two-tailed test was
considered for all statistical tests. The level of significance was
p,0.05.
Sample size for the estimation of vitamins and
homocysteine
Although the data for demographic and clinical parameters
were collected for all 400 subjects, the actual minimum required
sample size for vitamins and homocysteine was determined
assuming 95% CI and 80% power and using SD of respective
Diabetic Retinopathy - Vitamin-B12 Deficiency
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homocysteine were obtained on a subsample. Nevertheless, the
sample size was increased for homocysteine and vitamin B12, for
strengthening their association with DR.
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